Results 61 to 70 of about 11,960 (207)
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial [PDF]
Background: Late treatment failures after artemisinin-based combination therapies (ACTs) for falciparum malaria have increased in the Greater Mekong subregion in southeast Asia.
Hien, Tran Tinh +43 more
core +1 more source
Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. [PDF]
BACKGROUND: Resistance of malaria parasites to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) is increasing in prevalence in Africa. Combination therapy can both improve treatment and provide important public health benefits if it curbs the spread ...
Neal Alexander (18417) +39 more
core +1 more source
Safety of Artemether-Lumefantrine Exposure in First Trimester of Pregnancy: An Observational Cohort. [PDF]
There is limited data available regarding safety profile of artemisinins in early pregnancy. They are, therefore, not recommended by WHO as a first-line treatment for malaria in first trimester due to associated embryo-foetal toxicity in animal studies ...
Abdulla, Salim +17 more
core +1 more source
Despite repeated malaria infection, individuals living in malaria endemic areas remain vulnerable to re-infection. The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when ...
El Gaaloul, Myriam +15 more
core +1 more source
Infants and children under five years generally have high susceptibility to pathogenic and opportunistic infections due to immaturity and inexperience of their immune responses.
Solomon Opoku, Isaac Nyanor
doaj +1 more source
Highly lipophilic antimalarial drugs, artemether and lumefantrine, whilst an effective fixed-dose combination treatment to lower the malarial disease burden, are therapeutically hindered by low aqueous solubility and varied bioavailability.
Christi A. Wilkins +2 more
doaj +1 more source
ABSTRACT Severe malaria remains a major cause of acute kidney injury and multiorgan failure in endemic regions, often requiring renal replacement therapy. However, access to dialysis is limited in many resource‐constrained settings, making outcomes highly dependent on early diagnosis and effective antimalarial treatment. We report a 32‐year‐old man who
Tamirat Godebo Woyimo +8 more
wiley +1 more source
Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. [PDF]
BACKGROUND: Artemisinin-based combination therapy (ACT) reduces the potential for malaria transmission, compared with non-ACTs. It is unclear whether this effect differs between ACTs.
Sauerwein, Robert W +46 more
core +1 more source
Aim This study intends to assess the pharmacokinetic properties and treatment response of lumefantrine in pregnant and non‐pregnant women with uncomplicated Plasmodium falciparum malaria infection in Western Kenya. Methods Seventy‐five women with uncomplicated P.
Elizabeth Juma +9 more
wiley +1 more source
Health worker performance in the management of paediatric fevers following in-service training and exposure to job aids in Kenya. [PDF]
BACKGROUND: Improving the way artemether-lumefantrine (AL) is provided to patients attending clinics is critical to maximize the benefit of this new medicine.
Zurovac, D +19 more
core +1 more source

